Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • FROM THE ANALYST'S COUCH

The significance of blockbusters in the pharmaceutical industry

  1. Alexander Schuhmacher

    1. Technische Hochschule Ingolstadt, Ingolstadt, Germany; University of St. Gallen Institute of Technology Management, St Gallen, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Markus Hinder

    1. Novartis Global Drug Development, Basel, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Nikolaj Boger

    1. University of St. Gallen Institute of Technology Management, St Gallen, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Dominik Hartl

    1. Granite Bio, Basel, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. Oliver Gassmann

    1. University of St. Gallen Institute of Technology Management, St Gallen, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Marketed products with total annual sales of >US$1 billion, termed ‘blockbusters’, have historically provided the financial basis for most research-based pharmaceutical companies to sustain their innovation-driven research and development (R&D) models. Previous analyses indicated that pharmaceutical companies are increasingly struggling to deliver blockbusters, suggesting that the traditional blockbuster model might be broken. We evaluated the recent significance of blockbusters by analysing new drugs (new molecular entities or new biologics) developed by the 20 leading research-based pharmaceutical companies over the last decade (2011–2020) to assess whether the blockbuster model is still valid or indeed broken (see Supplementary information for details of the dataset and analysis).

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 22, 177-178 (2023)

doi: https://doi.org/10.1038/d41573-022-00213-z

Supplementary Information

  1. Supplementary information
  2. Supplementary Table 1

Competing Interests

A.S., N.B. and O.G. declare no competing interests. M.H. is an employee of Novartis and a former employee of Roche and Sanofi. D.H. is a former employee of Roche and Novartis. This study did not get any external funding and was undertaken independently.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links